Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

The Schwab U.S. Dividend Equity ETF (SCHD) pulled in $679.26 million over five trading days as its share price climbed 2.39%, TipRanks reported.

Three of the fund's biggest holdings made news in the same stretch, adding fresh fuel to a monthslong rotation out of growth and into defensive dividend payers. The March reconstitution had already reshaped what that money was buying.

Merck, Abbott, and Amgen powered the weekly surge

Merck's partnership with Moderna on intismeran autogene, a personalized mRNA cancer vaccine, met its primary endpoint of recurrence-free survival in combination with Keytruda in the Phase 3 INTerpath-001 melanoma trial announced Aug. 19, 2026, according to Merck's press release.

Moderna CEO Stéphane Bancel called the mRNA trial data a pivotal moment for personalized cancer therapy.

For many years, the idea of creating an mRNA treatment designed specifically for an individual patient's cancer was aspirational. We are now helping turn that vision into a reality.

Morgan Stanley upgraded Merck to Overweight from Equalweight and lifted its price target to $179 from $116, while UBS raised its target to $175 from $145 and Goldman Sachs raised its target to $160 from $140, both keeping Buy ratings, TipRanks reported on Aug. 20, 2026.

A settlement of infant-formula litigation also lifted the stock. Abbott is SCHD's largest holding at about 4.78% of assets as of Aug. 13, 2026, according to TopDividendETFs.

Amgen launched its Phase 3 DeLLphi-315 trial testing a subcutaneous version of its lung-cancer drug tarlatamab and completed a Phase 1 study comparing two formulations of its cholesterol drug evolocumab, TipRanks confirmed.

The March reconstitution reshaped SCHD's portfolio

The fund's annual reconstitution took effect on March 23, 2026, adding 25 stocks and removing 22 from the Dow Jones U.S. Dividend 100 Index, the Motley Fool reported.

Major additions included UnitedHealth Group, Procter & Gamble, Qualcomm, and Accenture. Energy exposure dropped by roughly 8 percentage points, falling from about 21% to 13%, Seeking Alpha reported.

Healthcare rose 4 percentage points, and technology added 3. Tech weight climbed from 11% to more than 15% by early June, the Motley Fool reported at the time.

The March reconstitution improved SCHD's quality screens, but the tech drift from 11% toward 15% before quarterly rebalancing pulled it back to 8.75% shows how quickly the fund's risk character can shift between reconstitutions.

Healthcare at 21.05% and consumer staples at 19.32% still anchor the portfolio, according to TopDividendETFs, and together they represent more than 40% of the fund.

Story Continues

SCHD's March reconstitution reshaped sector exposure, boosting healthcare and technology while reducing energy and shifting the fund's overall risk profile.AFP Contributor / Getty Images

A stalled Fed kept the rotation running

SCHD has returned about 30.11% year to date through Aug. 21, 2026, outpacing the S&P 500's 12.11% return by roughly 18 percentage points, 24/7 Wall St reported.

That reversed three years of underperformance from 2023 through 2025, HNGN noted. The federal funds rate sits at 3.50% to 3.75% after five consecutive holds through July 2026, Trading Economics data confirm.

Nine of the 18 officials who submitted projections supported at least one increase in the June dot plot, and Fed Chair Kevin Warsh did not submit a dot, according to the Fed's June Summary of Economic Projections.

More Charles Schwab:

Charles Schwab, Fidelity sound alarm on Roth IRA rule Morgan Stanley doubles down on Schwab after earnings Schwab plots S&P 500 prediction markets push with Cboe

Three members dissented at the July 29 meeting in favor of a hike. Futures markets priced a September rate increase at about 40% probability as of Aug. 12, 2026, Forbes reported.

MUFG projected the Fed staying on hold through the year-end, with easing pushed to early 2027.

SCHD's trailing dividend yield of about 3.08% compares favorably with the Vanguard Dividend Appreciation ETF (VIG) at 1.69% and the iShares Core Dividend Growth ETF (DGRO) at 1.72%, according to Dividend Vision data as of July 22, 2026.

Its price-to-earnings ratio of about 19 also reflects a discount to the S&P 500, according to The Motley Fool, reinforcing the value case drawing billions into dividend strategies.

3 risks that could stall the SCHD rotation trade

The rotation isn't guaranteed to hold. Three forces could reverse it.

Megacap tech reclaiming leadership: An April 2026 tech rally briefly compressed SCHD's relative gains, showing how quickly growth sentiment can shift the balance, the Motley Fool reported. Concentration risk from rebalancing: The March reconstitution briefly lifted tech to over 15% and put Qualcomm and Texas Instruments in the top two spots, the Motley Fool flagged in June. Since then, quarterly rebalancing has reversed that shift, tech is back to 8.75% as of Aug. 13, 2026. Yield compression versus Treasuries: SCHD's trailing yield has fallen from about 3.60% at reconstitution to 3.09% as the price rallied. The 30-year Treasury now out-yields dividend stocks by 2.2 percentage points, the Motley Fool reported.

Source:Motley Fool analysis of SCHD

SCHD's strongest week signals a broader shift in investor positioning

The $679 million weekly inflow reflects a 2026 rotation into defensive dividend names, not an isolated spike. Healthcare and consumer staples at roughly 41% of the fund anchor the trade, while Merck, Abbott, and Amgen catalysts gave the latest push.

The rotation's durability hinges on the Fed staying on hold, inflation not reaccelerating, and tech stocks not reasserting dominance.

What isn't yet clear is how long dividend yields near 3% can hold investor attention when a 30-year Treasury pays over 5% risk-free, or whether the March reconstitution's tighter quality screens will insulate SCHD if growth leadership snaps back.

Both questions get answered in the next few Fed meetings, not in the next few weeks of inflow data.

Related: Schwab SCHD holders are missing its ideal dividend ETF match

This story was originally published by TheStreet on Aug 25, 2026, where it first appeared in the Investing section. Add TheStreet as a Preferred Source by clicking here.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Photo by Pexels on Pixabay

Boston Scientific is back on familiar ground, but the business arriving this time is not the same. Will a history of strong bounces matter more than a future of weaker growth?

Boston Scientific (BSX), a maker of medical devices from coronary catheters to neuromodulators, has seen its stock slide. Now trading around $49.01 a share, it has settled back into a price zone between $46.56 and $51.46 where buyers have, in the past, drawn a firm line. This floor has been tested and defended six separate times.

History says buyers show up here. The question every investor watching this pullback must answer is, will they this time? The table of prior bounces shows a pattern of sharp recoveries, but a pattern is not a promise. The business arriving at the floor today is what will decide if it holds or breaks.

How strong were the prior defenses?

The historical record at this level is strong. Across six previous visits to this price zone, buyers consistently stepped in to halt the decline, though the resulting rebounds were largely modest. The table of prior bounces reveals that five of the six defenses generated only single-digit to low-double-digit moves over several weeks, with just one multi-year outlier driving the historical average. The level has historically acted as support, but an immediate surge is far from guaranteed.

Other episodes were more profound. Excluding the multi-year advance that began in late 2023, the prior short-term defenses yielded a median peak gain of 8.6% across holding periods of 11 to 47 days. The October 2023 visit was a distinct outlier: rather than a quick test-and-rebound, it kicked off an extended bull run that peaked at a 122% gain nearly two years later before round-tripping back to this support band.

Bounce Date Peak Gain After Holding Days To That Peak 2/2/2023 1.6% 47 3/23/2023 10.3% 27 4/26/2023 5.2% 20 5/30/2023 8.2% 23 8/18/2023 8.9% 11 10/12/2023 122% 697

Why is the business arriving at this floor weaker?

A stock doesn't revisit a support level by accident. While Boston Scientific's broader business looks healthy, with trailing twelve-month revenue growth of 13.5% and a trailing GAAP price-to-earnings multiple of 19.6, specific segments are under severe pressure. Management has cut its full-year 2026 guidance for adjusted EPS to a range of $3.28 to $3.32.

The reason for the downgrade is concentrated in two former high-growth engines. Management states the U.S. market for its WATCHMAN heart device has "slowed sharply and unexpectedly, primarily driven by compounding clinical evidence, which has impacted referral patterns." At the same time, in its Electrophysiology (EP) business, the company "did not anticipate the degree of competitive share movement we're now seeing in the U.S. market." These are not minor issues; management now expects "limited adjusted EPS growth" in 2027. The company is pinning its hopes for a 2028 rebound on a new slate of products. An interesting question for investors is whether they are still holding Boston Scientific stock for its next device. For those who prefer to own the theme rather than a single name, a broader healthcare ETF like XLV offers exposure to the entire sector.

Story Continues

What decides if the pattern breaks?

The standoff at this level is a direct conflict between a powerful historical pattern and a newly weakened near-term business outlook. The core of the company, representing roughly 75% of revenue, is expected to grow approximately 6%. But the market is focused on the trouble spots. The one to watch is the WATCHMAN device.

Management has been explicit, guiding for global WATCHMAN growth in the second half of 2026 to be "declining mid- to high-single digits on a year-over-year basis." This is the specific trend that will likely determine whether the historical floor holds. If that rate of decline stabilizes or shows signs of bottoming, buyers may see an opportunity. If it worsens, the memory of six prior bounces may not be enough to prevent a seventh test from failing.

For more stocks testing historically significant support levels, our Buy the Dip screen monitors these inflection points daily.

One Stock At A Crossroads Should Not Decide Your Year

A stock testing its support is a stock at a decision point, and decision points cut both ways. Concentrated holders feel every one of them at full force.

The Trefis High Quality (HQ) Portfolio spreads those moments across roughly 30 quality businesses in different industries, so no single stock's crossroads decides the outcome. It has a track record of outpacing a benchmark that combines the three major indices - the S&P 500, S&P Mid-cap, and Russell 2000. Follow the drama; diversify the stakes.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Labcorp Holdings Inc. LH dürfte von erweiterten Testkapazitäten in wachstumsstarken Bereichen wie Neurologie und Autoimmunerkrankungen profitieren. Im vergangenen Jahr stieg die Aktie um 21,9 %, gegenüber 13,4 % für die Branche und 20,8 % für den S&P 500. Die Marktkapitalisierung beträgt 27,28 Mrd. US-Dollar. Labcorp erzielte in den vergangenen vier Quartalen eine durchschnittliche Gewinnüberraschung von 3,1 %. Spezialtests in Onkologie, Frauengesundheit, Autoimmunerkrankungen und Neurologie verzeichneten im ersten Halbjahr 2026 ein zweistelliges Umsatzwachstum. Im zweiten Quartal schloss das Unternehmen Übernahmen von Laborleistungen von Parkview Health und Tribal Diagnostics ab und erhielt einen weiteren Auftrag des Verteidigungsministeriums. Die Nettoübernahmen trugen 1,2 % zum Unternehmensumsatzwachstum und 1,9 % zum Wachstum der Diagnostik bei. Labcorp verfügte am Ende des zweiten Quartals über 141,8 Mio. US-Dollar an liquiden Mitteln, tilgte vorrangige Schuldverschreibungen über 500 Mio. US-Dollar, kaufte Aktien für 353,8 Mio. US-Dollar zurück und zahlte 58,7 Mio. US-Dollar an Dividenden. Die Konsensschätzung für den Gewinn je Aktie 2026 stieg auf 18,28 US-Dollar; die Umsatzschätzung liegt bei 14,75 Mrd. US-Dollar. Globus Medical, Veracyte und Teleflex werden als besser bewertete Aktien genannt. Der Text endet während eines Werbehinweises.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Labcorp Holdings Inc. LH dürfte von erweiterten Testkapazitäten in wachstumsstarken Bereichen wie Neurologie und Autoimmunerkrankungen profitieren. Im vergangenen Jahr stieg die Aktie um 21,9 %, gegenüber 13,4 % für die Branche und 20,8 % für den S&P 500. Die Marktkapitalisierung beträgt 27,28 Mrd. US-Dollar. Labcorp erzielte in den vergangenen vier Quartalen eine durchschnittliche Gewinnüberraschung von 3,1 %. Spezialtests in Onkologie, Frauengesundheit, Autoimmunerkrankungen und Neurologie verzeichneten im ersten Halbjahr 2026 ein zweistelliges Umsatzwachstum. Im zweiten Quartal schloss das Unternehmen Übernahmen von Laborleistungen von Parkview Health und Tribal Diagnostics ab und erhielt einen weiteren Auftrag des Verteidigungsministeriums. Die Nettoübernahmen trugen 1,2 % zum Unternehmensumsatzwachstum und 1,9 % zum Wachstum der Diagnostik bei. Labcorp verfügte am Ende des zweiten Quartals über 141,8 Mio. US-Dollar an liquiden Mitteln, tilgte vorrangige Schuldverschreibungen über 500 Mio. US-Dollar, kaufte Aktien für 353,8 Mio. US-Dollar zurück und zahlte 58,7 Mio. US-Dollar an Dividenden. Die Konsensschätzung für den Gewinn je Aktie 2026 stieg auf 18,28 US-Dollar; die Umsatzschätzung liegt bei 14,75 Mrd. US-Dollar. Globus Medical, Veracyte und Teleflex werden als besser bewertete Aktien genannt. Der Text endet während eines Werbehinweises.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.

What Is Driving Fresh Interest In CONMED Stock Today

CONMED (CNMD) is back in focus as investors assess the adoption of its AirSeal, Buffalo Filter, and BioBrace platforms, along with tariff headwinds and slower AirSeal growth, in the context of the company's broader earnings profile.

See our latest analysis for CONMED.

CONMED's share price has moved to US$49.25 after a strong 30 day share price return of 14% and a 90 day share price return of 36.12%. However, the 1 year total shareholder return is still down 7.4%. This suggests momentum has picked up recently while longer term holders remain under water.

If the recent move in CONMED has you looking beyond a single stock, this is a good moment to broaden your search and uncover 40 healthcare AI stocks.

CONMED has a broad surgical portfolio and fresh share price momentum after recent gains. The real test now is whether that improving sentiment lines up with what you are actually paying for the business.

Most Popular Narrative: 8.2% Overvalued

On the most followed valuation narrative, CONMED's fair value sits at $45.50 compared with the last close at $49.25, which puts investors slightly ahead of that reference point and makes the underlying assumptions worth a closer look.

The accelerating adoption of minimally invasive and robotic-assisted surgeries, combined with CONMED's strong positioning via AirSeal and BioBrace (including expanding use cases and positive clinical feedback), is expected to support durable procedure volume growth and increase recurring revenue, contributing to sustained top-line growth.

Read the complete narrative.

Want to see how this growth story is built? The narrative relies on rising procedure volumes, improving margins and a future earnings profile that looks very different to today.

Result: Fair Value of $45.50 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, CONMED still faces pressure from supply chain recovery issues and its reliance on hospital capital budgets, which could challenge the upbeat narrative if conditions tighten.

Find out about the key risks to this CONMED narrative.

Another View On CONMED's Valuation

The first narrative frames CONMED as 8.2% overvalued relative to a fair value of $45.50. Using P/E tells a different story. At 26.1x earnings, CONMED trades below peers at 33x and below a fair ratio of 32.1x, which points to potential upside if sentiment shifts.

Story Continues

For investors who lean more on earnings multiples than cash flow models, that gap suggests the market is pricing in extra execution risk rather than paying up for future growth. The question is whether you think that discount reflects hidden problems or a possible opportunity.

See what the numbers say about this price — find out in our valuation breakdown.NYSE:CNMD P/E Ratio as at Aug 2026

Next Steps

If the mixed signals around CONMED have you unsure, it makes sense to move quickly and look through the numbers yourself. To weigh both the concerns and the potential upsides in one place, review the 3 key rewards and 3 important warning signs.

Looking For More Ideas Beyond CONMED?

If CONMED has sharpened your focus, do not stop here. Use these screens to quickly spot other opportunities that could fit your approach.

Capture potential mispricing by reviewing 53 high quality undervalued stocks that combine strong fundamentals with prices that may not fully reflect their profiles. Strengthen your income watchlist by scanning 10 dividend fortresses that aim to pair higher yields with resilient business models. Prioritise capital preservation by assessing 80 resilient stocks with low risk scores that show lower risk scores while still offering room for returns.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include CNMD.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.

What Is Driving Fresh Interest In CONMED Stock Today

CONMED (CNMD) is back in focus as investors assess the adoption of its AirSeal, Buffalo Filter, and BioBrace platforms, along with tariff headwinds and slower AirSeal growth, in the context of the company's broader earnings profile.

See our latest analysis for CONMED.

CONMED's share price has moved to US$49.25 after a strong 30 day share price return of 14% and a 90 day share price return of 36.12%. However, the 1 year total shareholder return is still down 7.4%. This suggests momentum has picked up recently while longer term holders remain under water.

If the recent move in CONMED has you looking beyond a single stock, this is a good moment to broaden your search and uncover 40 healthcare AI stocks.

CONMED has a broad surgical portfolio and fresh share price momentum after recent gains. The real test now is whether that improving sentiment lines up with what you are actually paying for the business.

Most Popular Narrative: 8.2% Overvalued

On the most followed valuation narrative, CONMED's fair value sits at $45.50 compared with the last close at $49.25, which puts investors slightly ahead of that reference point and makes the underlying assumptions worth a closer look.

The accelerating adoption of minimally invasive and robotic-assisted surgeries, combined with CONMED's strong positioning via AirSeal and BioBrace (including expanding use cases and positive clinical feedback), is expected to support durable procedure volume growth and increase recurring revenue, contributing to sustained top-line growth.

Read the complete narrative.

Want to see how this growth story is built? The narrative relies on rising procedure volumes, improving margins and a future earnings profile that looks very different to today.

Result: Fair Value of $45.50 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, CONMED still faces pressure from supply chain recovery issues and its reliance on hospital capital budgets, which could challenge the upbeat narrative if conditions tighten.

Find out about the key risks to this CONMED narrative.

Another View On CONMED's Valuation

The first narrative frames CONMED as 8.2% overvalued relative to a fair value of $45.50. Using P/E tells a different story. At 26.1x earnings, CONMED trades below peers at 33x and below a fair ratio of 32.1x, which points to potential upside if sentiment shifts.

Story Continues

For investors who lean more on earnings multiples than cash flow models, that gap suggests the market is pricing in extra execution risk rather than paying up for future growth. The question is whether you think that discount reflects hidden problems or a possible opportunity.

See what the numbers say about this price — find out in our valuation breakdown.NYSE:CNMD P/E Ratio as at Aug 2026

Next Steps

If the mixed signals around CONMED have you unsure, it makes sense to move quickly and look through the numbers yourself. To weigh both the concerns and the potential upsides in one place, review the 3 key rewards and 3 important warning signs.

Looking For More Ideas Beyond CONMED?

If CONMED has sharpened your focus, do not stop here. Use these screens to quickly spot other opportunities that could fit your approach.

Capture potential mispricing by reviewing 53 high quality undervalued stocks that combine strong fundamentals with prices that may not fully reflect their profiles. Strengthen your income watchlist by scanning 10 dividend fortresses that aim to pair higher yields with resilient business models. Prioritise capital preservation by assessing 80 resilient stocks with low risk scores that show lower risk scores while still offering room for returns.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include CNMD.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.

What Is Driving Fresh Interest In CONMED Stock Today

CONMED (CNMD) is back in focus as investors assess the adoption of its AirSeal, Buffalo Filter, and BioBrace platforms, along with tariff headwinds and slower AirSeal growth, in the context of the company's broader earnings profile.

See our latest analysis for CONMED.

CONMED's share price has moved to US$49.25 after a strong 30 day share price return of 14% and a 90 day share price return of 36.12%. However, the 1 year total shareholder return is still down 7.4%. This suggests momentum has picked up recently while longer term holders remain under water.

If the recent move in CONMED has you looking beyond a single stock, this is a good moment to broaden your search and uncover 40 healthcare AI stocks.

CONMED has a broad surgical portfolio and fresh share price momentum after recent gains. The real test now is whether that improving sentiment lines up with what you are actually paying for the business.

Most Popular Narrative: 8.2% Overvalued

On the most followed valuation narrative, CONMED's fair value sits at $45.50 compared with the last close at $49.25, which puts investors slightly ahead of that reference point and makes the underlying assumptions worth a closer look.

The accelerating adoption of minimally invasive and robotic-assisted surgeries, combined with CONMED's strong positioning via AirSeal and BioBrace (including expanding use cases and positive clinical feedback), is expected to support durable procedure volume growth and increase recurring revenue, contributing to sustained top-line growth.

Read the complete narrative.

Want to see how this growth story is built? The narrative relies on rising procedure volumes, improving margins and a future earnings profile that looks very different to today.

Result: Fair Value of $45.50 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, CONMED still faces pressure from supply chain recovery issues and its reliance on hospital capital budgets, which could challenge the upbeat narrative if conditions tighten.

Find out about the key risks to this CONMED narrative.

Another View On CONMED's Valuation

The first narrative frames CONMED as 8.2% overvalued relative to a fair value of $45.50. Using P/E tells a different story. At 26.1x earnings, CONMED trades below peers at 33x and below a fair ratio of 32.1x, which points to potential upside if sentiment shifts.

Story Continues

For investors who lean more on earnings multiples than cash flow models, that gap suggests the market is pricing in extra execution risk rather than paying up for future growth. The question is whether you think that discount reflects hidden problems or a possible opportunity.

See what the numbers say about this price — find out in our valuation breakdown.NYSE:CNMD P/E Ratio as at Aug 2026

Next Steps

If the mixed signals around CONMED have you unsure, it makes sense to move quickly and look through the numbers yourself. To weigh both the concerns and the potential upsides in one place, review the 3 key rewards and 3 important warning signs.

Looking For More Ideas Beyond CONMED?

If CONMED has sharpened your focus, do not stop here. Use these screens to quickly spot other opportunities that could fit your approach.

Capture potential mispricing by reviewing 53 high quality undervalued stocks that combine strong fundamentals with prices that may not fully reflect their profiles. Strengthen your income watchlist by scanning 10 dividend fortresses that aim to pair higher yields with resilient business models. Prioritise capital preservation by assessing 80 resilient stocks with low risk scores that show lower risk scores while still offering room for returns.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include CNMD.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.

What Is Driving Fresh Interest In CONMED Stock Today

CONMED (CNMD) is back in focus as investors assess the adoption of its AirSeal, Buffalo Filter, and BioBrace platforms, along with tariff headwinds and slower AirSeal growth, in the context of the company's broader earnings profile.

See our latest analysis for CONMED.

CONMED's share price has moved to US$49.25 after a strong 30 day share price return of 14% and a 90 day share price return of 36.12%. However, the 1 year total shareholder return is still down 7.4%. This suggests momentum has picked up recently while longer term holders remain under water.

If the recent move in CONMED has you looking beyond a single stock, this is a good moment to broaden your search and uncover 40 healthcare AI stocks.

CONMED has a broad surgical portfolio and fresh share price momentum after recent gains. The real test now is whether that improving sentiment lines up with what you are actually paying for the business.

Most Popular Narrative: 8.2% Overvalued

On the most followed valuation narrative, CONMED's fair value sits at $45.50 compared with the last close at $49.25, which puts investors slightly ahead of that reference point and makes the underlying assumptions worth a closer look.

The accelerating adoption of minimally invasive and robotic-assisted surgeries, combined with CONMED's strong positioning via AirSeal and BioBrace (including expanding use cases and positive clinical feedback), is expected to support durable procedure volume growth and increase recurring revenue, contributing to sustained top-line growth.

Read the complete narrative.

Want to see how this growth story is built? The narrative relies on rising procedure volumes, improving margins and a future earnings profile that looks very different to today.

Result: Fair Value of $45.50 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, CONMED still faces pressure from supply chain recovery issues and its reliance on hospital capital budgets, which could challenge the upbeat narrative if conditions tighten.

Find out about the key risks to this CONMED narrative.

Another View On CONMED's Valuation

The first narrative frames CONMED as 8.2% overvalued relative to a fair value of $45.50. Using P/E tells a different story. At 26.1x earnings, CONMED trades below peers at 33x and below a fair ratio of 32.1x, which points to potential upside if sentiment shifts.

Story Continues

For investors who lean more on earnings multiples than cash flow models, that gap suggests the market is pricing in extra execution risk rather than paying up for future growth. The question is whether you think that discount reflects hidden problems or a possible opportunity.

See what the numbers say about this price — find out in our valuation breakdown.NYSE:CNMD P/E Ratio as at Aug 2026

Next Steps

If the mixed signals around CONMED have you unsure, it makes sense to move quickly and look through the numbers yourself. To weigh both the concerns and the potential upsides in one place, review the 3 key rewards and 3 important warning signs.

Looking For More Ideas Beyond CONMED?

If CONMED has sharpened your focus, do not stop here. Use these screens to quickly spot other opportunities that could fit your approach.

Capture potential mispricing by reviewing 53 high quality undervalued stocks that combine strong fundamentals with prices that may not fully reflect their profiles. Strengthen your income watchlist by scanning 10 dividend fortresses that aim to pair higher yields with resilient business models. Prioritise capital preservation by assessing 80 resilient stocks with low risk scores that show lower risk scores while still offering room for returns.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include CNMD.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.

Abbott Laboratories stock has delivered a 14.0% total return over the past three years, yet its current checks suggest a mixed valuation picture as the Discounted Cash Flow (DCF) estimate points to meaningful upside while market multiples look closer to fair.

A 14.0% return over three years indicates that long term holders have seen moderate gains, even though shorter term returns have recently been weaker. Partnerships such as supplying sensors for MiniMed Flex and the Lingo data collaboration with Google Health can support expectations for future cash flows, while execution risk around product adoption and data driven health offerings may weigh on how much value the market is willing to ascribe. Abbott Laboratories scores 3 out of 6 on valuation checks, which points to a mixed picture rather than a clear bargain or clear overvaluation.

For investors, the debate is whether the current share price around US$111.25 still leaves enough upside relative to the intrinsic value suggested by the DCF work.

Find out why Abbott Laboratories' -12.6% return over the last year is lagging behind its peers.

Is Abbott Laboratories Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) method estimates what Abbott Laboratories could be worth based on its projected future cash generation. For Abbott Laboratories, the latest twelve month free cash flow is about $7.6b, and the model applies a growing cash flow profile over the next decade to reflect expectations of continued business expansion.

Under these assumptions, the DCF model arrives at an intrinsic value of about $151 per share, compared with the current price around $111. This implies the stock is trading at roughly a 26.1% discount to that cash flow based estimate, so the shares appear undervalued within this framework. The new MiniMed Flex system using Abbott sensors illustrates how product partnerships can support the cash flow story, yet the market price remains below the value indicated by the DCF analysis.

Overall, the Discounted Cash Flow work suggests Abbott Laboratories stock appears undervalued relative to its projected cash generation.

Our Discounted Cash Flow (DCF) analysis suggests Abbott Laboratories is undervalued by 26.1%. Track this in your watchlist or portfolio, or discover 52 more high quality undervalued stocks.ABT Discounted Cash Flow as at Aug 2026

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Abbott Laboratories.

Story Continues

Is Abbott Laboratories Fairly Priced on Earnings?

The P/E multiple suits Abbott Laboratories because earnings remain a key anchor for how the market prices large, diversified healthcare groups. Right now the stock trades on a P/E of about 35.6x, which is higher than the Medical Equipment industry average of roughly 26.2x and above the peer group average of about 31.0x.

The tailored fair P/E ratio for Abbott Laboratories is estimated at about 36.9x, which is only slightly above where the stock currently trades. That small gap suggests the higher multiple versus the sector is largely in line with what the company profile, margins and risk level might warrant, rather than pointing to a clear premium or discount.

On the P/E measure, Abbott Laboratories stock appears roughly fairly valued relative to what the model indicates would be a reasonable earnings multiple.NYSE:ABT P/E Ratio as at Aug 2026

See what the numbers say about this price — find out in our valuation breakdown.

The Abbott Laboratories Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Abbott Laboratories valuation puzzle leaves off and clarify which assumptions on growth, margins and earnings would need to hold for the stock to be worth materially more or less than today's price on the Community page. Each Narrative presents fair value as a thesis about Abbott Laboratories' business that can be tracked over time, rather than a one off snapshot.

You can add your voice to the Simply Wall St community by sharing a Narrative on Abbott Laboratories' stock that sets out a clear, number driven case and tracks how it holds up as new results come through.

This is a chance to put forward a view on whether developments like Abbott Laboratories' role in the MiniMed Flex system and the Lingo collaboration with Google Health ultimately support the current share price or call for a different valuation story.

Do you think there's more to the story for Abbott Laboratories? Head over to our Community to see what others are saying!

The Bottom Line

For Abbott Laboratories, the Discounted Cash Flow (DCF) work points to meaningful upside, while the P/E based view suggests the stock is priced roughly in line with peers once its profile is factored in. The valuation checks therefore lean toward undervalued, but not in a way that overrides the mixed signals from the broader framework. The key question from here is whether Abbott Laboratories can convert its partnerships and product pipeline into the cash flows that justify the intrinsic value estimate, or whether the market is correct to keep a discount in place for execution risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ABT.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.

Abbott Laboratories stock has delivered a 14.0% total return over the past three years, yet its current checks suggest a mixed valuation picture as the Discounted Cash Flow (DCF) estimate points to meaningful upside while market multiples look closer to fair.

A 14.0% return over three years indicates that long term holders have seen moderate gains, even though shorter term returns have recently been weaker. Partnerships such as supplying sensors for MiniMed Flex and the Lingo data collaboration with Google Health can support expectations for future cash flows, while execution risk around product adoption and data driven health offerings may weigh on how much value the market is willing to ascribe. Abbott Laboratories scores 3 out of 6 on valuation checks, which points to a mixed picture rather than a clear bargain or clear overvaluation.

For investors, the debate is whether the current share price around US$111.25 still leaves enough upside relative to the intrinsic value suggested by the DCF work.

Find out why Abbott Laboratories' -12.6% return over the last year is lagging behind its peers.

Is Abbott Laboratories Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) method estimates what Abbott Laboratories could be worth based on its projected future cash generation. For Abbott Laboratories, the latest twelve month free cash flow is about $7.6b, and the model applies a growing cash flow profile over the next decade to reflect expectations of continued business expansion.

Under these assumptions, the DCF model arrives at an intrinsic value of about $151 per share, compared with the current price around $111. This implies the stock is trading at roughly a 26.1% discount to that cash flow based estimate, so the shares appear undervalued within this framework. The new MiniMed Flex system using Abbott sensors illustrates how product partnerships can support the cash flow story, yet the market price remains below the value indicated by the DCF analysis.

Overall, the Discounted Cash Flow work suggests Abbott Laboratories stock appears undervalued relative to its projected cash generation.

Our Discounted Cash Flow (DCF) analysis suggests Abbott Laboratories is undervalued by 26.1%. Track this in your watchlist or portfolio, or discover 52 more high quality undervalued stocks.ABT Discounted Cash Flow as at Aug 2026

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Abbott Laboratories.

Story Continues

Is Abbott Laboratories Fairly Priced on Earnings?

The P/E multiple suits Abbott Laboratories because earnings remain a key anchor for how the market prices large, diversified healthcare groups. Right now the stock trades on a P/E of about 35.6x, which is higher than the Medical Equipment industry average of roughly 26.2x and above the peer group average of about 31.0x.

The tailored fair P/E ratio for Abbott Laboratories is estimated at about 36.9x, which is only slightly above where the stock currently trades. That small gap suggests the higher multiple versus the sector is largely in line with what the company profile, margins and risk level might warrant, rather than pointing to a clear premium or discount.

On the P/E measure, Abbott Laboratories stock appears roughly fairly valued relative to what the model indicates would be a reasonable earnings multiple.NYSE:ABT P/E Ratio as at Aug 2026

See what the numbers say about this price — find out in our valuation breakdown.

The Abbott Laboratories Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Abbott Laboratories valuation puzzle leaves off and clarify which assumptions on growth, margins and earnings would need to hold for the stock to be worth materially more or less than today's price on the Community page. Each Narrative presents fair value as a thesis about Abbott Laboratories' business that can be tracked over time, rather than a one off snapshot.

You can add your voice to the Simply Wall St community by sharing a Narrative on Abbott Laboratories' stock that sets out a clear, number driven case and tracks how it holds up as new results come through.

This is a chance to put forward a view on whether developments like Abbott Laboratories' role in the MiniMed Flex system and the Lingo collaboration with Google Health ultimately support the current share price or call for a different valuation story.

Do you think there's more to the story for Abbott Laboratories? Head over to our Community to see what others are saying!

The Bottom Line

For Abbott Laboratories, the Discounted Cash Flow (DCF) work points to meaningful upside, while the P/E based view suggests the stock is priced roughly in line with peers once its profile is factored in. The valuation checks therefore lean toward undervalued, but not in a way that overrides the mixed signals from the broader framework. The key question from here is whether Abbott Laboratories can convert its partnerships and product pipeline into the cash flows that justify the intrinsic value estimate, or whether the market is correct to keep a discount in place for execution risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ABT.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

View Comments